article · Journal of Antimicrobial Chemotherapy

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

Lufina Tsirizani
Alexander J. Szubert
Chishala Chabala
Hylke Waalewijn
Helen McIlleron
Victor Musiime
Diana M. Gibb
Shaghayegh Mohsenian Naghani
Veronica Mulenga
Mariam Kasozi
Mutsa Bwakura‐Dangarembizi
Roeland E. Wasmann
Lara Monkiewicz
Diana Antonia Rutebarika
Moses Chitsamatanga
Abbas Lugemwa
David M Burger
Paolo Denti
Angela Colbers

20244 citationsOpen accessMakerere University

Abstract

Darunavir exposures achieved in our trial are within safe range. Darunavir/ritonavir can safely be co-administered with TAF/FTC. Both WHO-recommended 600/100 mg and CHAPAS-4 800/100 mg darunavir/ritonavir doses for the 25-34.9 kg weight band offer favourable exposures. The choice between them can depend on tablet availability.

Research topics

HIV/AIDS drug development and treatment
Pharmacological Effects and Toxicity Studies
HIV Research and Treatment

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/jac/dkae319

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.